Lung cancer fast turning into epidemic in India

IMT News Desk
IMT News Desk
· 5 min read
(L-R)Dr. KS Satish, Consultant Pulmonologist & Chest Physician,Dr. Niti Raizada, Sr. Consultant Medical Oncologist and Hemato-oncologist,Dr. Suraj Manjunath, Consultant Onco-surgeon, Vikram Hospital, Bengaluru
  • Lung cancer today accounts for higher number of deaths in the country than colorectal cancer, prostate cancer and breast cancer
  • Only 15 percent of cases of lung cancer are curable at the time of diagnosis. In fact, if lung cancer is detected by chest X-ray, it is already too late for the patient
  • Lung cancer accounts for 5.9% of all new cancer cases diagnosed in India (both sex combined)
  • On occasion of World Lung Cancer Awareness Month in November, Vikram Hospital is offering lung cancer screening program and smoking cessation therapy

BENGALURU / November 23, 2018: Data from Indian Council of Medical Research (ICMR) suggests that lung cancer is fast turning into an epidemic in India. It is a high-mortality cancer due to late stage at diagnosis and poor access to affordable healthcare, and today accounts for higher number of deaths in the country than colorectal cancer, prostate cancer and breast cancer. This was said by oncologists from Vikram Hospital, Bengaluru, who were speaking at a workshop to create awareness about lung cancer in the city. Worldwide, November is observed as the lung cancer awareness month.

Said Dr. Niti Raizada, Sr. Consultant Medical Oncologist and Hemato-oncologist, Vikram Hospital, Bengaluru: “Only 15 percent of cases of lung cancer are curable at the time of diagnosis. Patients with lung cancer present themselves for diagnosis at a much later stage than other cancers due to the nature of the disease. Early on, people with lung cancer have no symptoms or vague symptoms. In fact, if lung cancer is detected by chest X-ray, it is already too late for the patient. The only effective method for screening lung cancer in early stages is the Low Dose Helical Lung CT, where high-resolution images pick up early lung lesions.”

Said Dr. Suraj Manjunath, Consultant Onco-surgeon, Vikram Hospital, Bengaluru: “Lung cancer has one of the highest morbidity and mortality among all cancers. It accounts for 14.5% of all cancers in men and 8.4% in women globally. It is a leading cause of cancer death in men worldwide at 22%, which means that one in five of all cancer deaths in men occur due to lung cancer. Lung cancer accounts for 5.9% of all new cancer cases diagnosed in India (both sex combined), while mortality is 8.82% of all cancers combined.”

“Smoking is the single largest contributor for lung cancer. Passive smoking, exposure to carcinogenic toxins like asbestos and radon, radiation and air pollutants are other causes, besides a small percentage of genetic cancer. Exposure of women to smoke from the burning of charcoal for cooking is also a cause of lung cancer. Physical activity may reduce the risk of lung cancer by about 20 percent. Exercise is known to improve lung function and reduce the danger of other diseases too. In the West, there is a small decrease in the number of smokers. However, such trend is not seen in India yet. Moreover, the country is seeing an emerging population of women smokers. The most common age group for lung cancer is 50-59 years,” Dr. Niti Raizada said.

Talking about prevention, Dr. KS Satish, Consultant Pulmonologist & Chest Physician, Vikram Hospital, Bengaluru, said: “It’s never too late for anyone to quit smoking. Quit by age 30 and you reduce the risk of smoking-related diseases by 90 percent! Quit by age 50 and you reduce the risk of smoking-related diseases by 50 percent. Quit by age 60 and you would live longer than smokers in your age group, according to data by the National Cancer Institute in US. In fact, 15 years after one quits smoking, the risk of lung cancer become the same as that of a non-smoker. Two out of every three patients with lung cancer are over 65 years of age, so one gets enough time in life to take steps to avoid this high-mortality disease.”

Said Dr. Somesh Mittal, CEO, Vikram Hospital, Bengaluru: “In India, the highest reported incidence of lung cancer is from Mizoram in both males and females. Its incidence in North East India can be as high as 45 per 100,000 population. The time trends of lung cancer show a significant rise in Delhi, Chennai and Bengaluru across both sexes. The incidence and pattern of lung cancer differ as per geographic region and ethnicity, and largely reflect the prevalence and pattern of smoking.”

On occasion of Lung Cancer Awareness Month in November, Vikram Hospital Bengaluru is running a lung cancer screening program for chronic smokers, including assessment by paramedical workers and, if required, a low-dose CT scan of the chest. The hospital also offers smoking cessation therapy through a dedicated clinic run by the department of medical oncology to help smokers quit smoking.
About Vikram Hospital

Vikram Hospital Bengaluru is a quaternary care, multi-specialty hospital. It provides high-quality care in all clinical disciplines and has outstanding capabilities in Cardiology, Cardiac Surgery, Neurology, Neuro Surgery, Stroke and Epilepsy, Orthopaedic and Trauma Care, Spine Surgery, Bariatric and Metabolic Surgery, Gastroenterology and Hepatobillary, Nephrology, Urology, Critical Care, Pulmonology, Endocrinology, Maxillofacial, ENT, Plastic Surgery, Medical and Surgical Oncology, Gynaecology, Cosmetology, Dental and Dermatology. Vikram Hospital’s world-class medical care and expertise have delivered excellent clinical outcomes. The hospital offers comprehensive services in a compassionate and caring environment. For more information, please visit www.vikramhospital.com.

For information on this press release, please contact Imprimis PR

Nitheen AS @ 9686227227 / Megha Gowda @ 9986470678

Read Next

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris
News
June 12, 2026

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of Winlevi® (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in […]
Article by: IMT News Desk
Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory
News
June 12, 2026

Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory

Thyrocare Technologies Limited has announced the set-up of its new diagnostic laboratory in Prayagraj, Uttar Pradesh, in association with SecondMedic. The new laboratory is equipped with advanced testing infrastructure and supported by trained professionals, enabling timely and error-free diagnostic results. It caters to both specialised and routine testing requirements, offering support to ongoing and preventive […]
Article by: IMT News Desk
AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
News
June 12, 2026

AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

AstraZeneca Pharma India Ltd. (AZPIL) announced that the Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Trastuzumab Deruxtecan 100 mg/5 mL vial lyophilized powder for concentrate for solution for infusion, in combination with Pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer. In India, HER2-positive breast […]
Article by: IMT News Desk
Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules
News
June 11, 2026

Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules

Alembic Pharmaceuticals Limited (Alembic) announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Larotrectinib Capsules, 25 mg and 100 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Vitrakvi Capsules, 25 mg and 100 mg, of […]
Article by: IMT News Desk